I’m sure the math may fall out that way, but im not sure if that’s a correct methodology or interpretation or not. Nevertheless, I’m really keen to see your mathematical workings- would you share them?
Also is there an international industry standard regards the way these types of clinical results must be statistically calculated and reported? If so, are your workings accommodating of this? Are BOT’s
I agree, if there is a calculation error, it’s not professional and perhaps as you say, not trivial, but I sense you are suggesting something more sinister, such as misleading information etc. or are you saying it’s just sloppy?
Your workings and thought process here would be helpful to understand. trying to figure out exactly what your suggesting.
Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-704
-
- There are more pages in this discussion • 297 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $689.3M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 37.5¢ | $1.784M | 4.691M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 248028 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 356327 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |